The LIN28/let-7 Pathway in Cancer.

Balzeau J, Menezes MR, Cao S, Hagan JP. · 2017

Read The LIN28/let-7 Pathway in Cancer. by Balzeau J, Menezes MR, Cao S, Hagan JP. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5368188.txt.

Introduction

Julien Balzeau, Miriam R. Menezes, Siyu Cao, and John P. Hagan reviewed a cancer gene path in Frontiers in Genetics in 2017. A family of tiny RNAs called let-7 normally holds tumors back. Its loss is the most common such loss in cancer and tracks with a poor outlook. Two kin proteins, LIN28A and LIN28B, cause that loss when they wake in a cell.

One of the pair grabs the young form of let-7 and calls in a tail adding enzyme. The tail blocks the tiny RNA's birth, so its guard work dies. Freed from the brake, growth genes like MYC and RAS run high. Mouse work shows that switching LIN28 on can start or speed tumors by this route. The review covers the pair's roles in cancer stem cells, spread, fuel use, and drug resistance.

Catalog record

CREATORBalzeau J, Menezes MR, Cao S, Hagan JP.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE80 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5368188

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The LIN28/let-7 Pathway in Cancer By Julien Balzeau, Miriam R. Menezes, Siyu Cao, John P. Hagan Published in: Frontiers in Genetics DOI: 10.3389/fgene.2017.00031 ABSTRACT Among all tumor suppressor microRNAs, reduced let-7 expression occurs most frequently in cancer and typically correlates with poor prognosis. Activation of either LIN28A or LIN28B, two highly related RNA binding proteins (RBPs) and proto-oncogenes, is responsible for the global post-transcriptional downregulation of the let-7 microRNA family observed in many cancers. Specifically, LIN28A binds the terminal loop of precursor let-7 and recruits the Terminal Uridylyl Transferase (TUTase) ZCCHC11 that polyuridylates pre-let-7, thereby blocking microRNA biogenesis and tumor suppressor function. For LIN28B, the precise mechanism responsible for let-7 inhibition remains controversial. Functionally, the decrease in let-7 microRNAs leads to overexpression of their oncogenic targets such as MYC, RAS, HMGA2, BLIMP1, among others. Furthermore, mouse models demonstrate that ectopic LIN28 expression is sufficient to drive and/or accelerate tumorigenesis via a let-7 dependent mechanism. In this review, the LIN28/let-7 pathway is discussed, emphasizing its role in tumorigenesis, cancer stem cell biology, metabolomics, metastasis, and resistance to ionizing radiation and several chemotherapies. Also, emerging evidence will be presented suggesting that molecular targeting of this pathway may provide therapeutic benefit in cancer. INTRODUCTION MicroRNAs (miRNAs) are small non-coding RNAs (~19–22 nucleotides in length) that play critical roles in post-transcriptional gene regulation (reviewed in Hagan and Croce, 2007; Lin and Gregory, 2015b; Connerty et al., 2016). In general, microRNAs are generated by a two-step process where the primary microRNA (pri-miR) transcript is cleaved in the nucleus by the Microprocessor complex to generate precursor microRNA (pre-miR) with a characteristic stem-loop structure. The pre-miR is exported to the cytoplasm where Dicer is responsible for generating the mature miRNA that is incorporated into the microRNA-induced silencing complex (miRISC). To exert their biological effect, microRNAs most frequently bind with imperfect complementarity to the 3′ UTR of their targets mRNAs leading to mRNA decay and/or translational inhibition. Studies using genetically engineered mouse models have revealed that miRNAs serve diverse functions in developmental and physiological processes. Dysregulated microRNA expression is associated with and functionally significant for many diseases including cancer. Of note, a recent study systemically evaluated the prognostic value of miRNA expression in human cancers (Nair et al., 2012). Specifically, decreased expression of the tumor suppressor let-7 microRNAs and increased expression of oncogenic miR-21 are most frequently associated with poor prognosis as determined by analysis of 46 studies on 20 different types of human cancers. The coordinate repression of the let-7 microRNA family is striking for two reasons. First, there are 12 members of the let-7 microRNA family located on eight chromosomes, where most cells express a handful of let-7 family members. Secondly, primary let-7 transcripts are still being actively transcribed in many cancers as well as in embryonic stem cells; however, mature let-7 is not being produced as expected. Ultimately, two highly conserved RNA-binding proteins, LIN28A and LIN28B, were shown to inhibit biogenesis of mammalian let-7 miRNAs through direct binding to either pre-let-7 and/or pri-let-7 (Heo et al., 2008, 2009; Newman et al., 2008; Rybak et al., 2008; Viswanathan et al., 2008; Hagan et al., 2009; Piskounova et al., 2011). Strikingly, we showed that inhibition of either LIN28A or LIN28B via siRNA led to regression of established human xenograft tumors in mice that expressed the targeted gene (Piskounova et al., 2011). This result was recapitulated by restoring let-7 expression using a microRNA mimic, implicating let-7 dependent functions of LIN28AB in tumor regression. For clarity throughout this review, LIN28AB will be used to refer collectively to both LIN28A and LIN28B. Also, it is worth noting that many publications refer to LIN28 (the official gene name for LIN28A) when in reality the study involved LIN28B. In addition to miRNAs, cancer stem cells (CSCs) represent another important target for the design of novel anticancer treatments. Unlike differentiated cancer cells present in many tumors, CSCs are a rare tumor cell population that has stem cell-like properties and are sufficient in small numbers to regrow tumors. They have the ability of self-renewal and can differentiate into heterogeneous types of tumor cells (O'Connor et al., 2014). While frontline cancer treatments are often effective against the bulk of the tumor, most chemotherapeutic drugs show poor efficacy against CSCs. Considerable evidence has shown that CSCs is one of the underlying mechanisms of tumor resistance to chemotherapy and radiation therapy and are often responsible for recurrence of more deadly disease. Not surprisingly, expression of LIN28A or LIN28B serves as CSC biomarkers in multiple cancers (Zhou et al., 2013). LIN28AB directly contributes to the regulation and maintenance of stemness of CSCs. Moreover, LIN28AB via a let-7 dependent mechanism confers resistance to ionizing radiation and several chemotherapies. STRUCTURE AND KEY BIOLOGICAL FUNCTIONS OF LIN28A AND LIN28B Lin-28 and let-7 were first discovered and studied in the nematode Caenorhabditis elegans as heterochronic genes that regulate developmental timing (Moss et al., 1997; Reinhart et al., 2000; Slack et al., 2000). In worms to mammals, Lin28 blocks let-7 expression, while let-7 itself binds to the 3′ UTR of Lin28 mRNA to regulate negatively Lin28 expression, thereby establishing a double negative feedback loop. In mammals, there are two LIN28 family members. The human LIN28A and LIN28B genes encode 209- and 250-amino acid proteins, respectively (Figure 1). Both RNA binding proteins (RBPs) share a high degree of homology in structural domains with an N-terminal cold-shock domain (CSD) and two C-terminal CysCysHisCys (CCHC) zinc finger domains (Guo et al., 2006). Crystallography and biochemical studies demonstrate that the CSD and Zinc finger domains bind GNGAY and GGAG motifs in the pre-let-7 terminal loop, respectively (Nam et al., 2011; Figure 2). The CSD and Zinc finger domains are separated by a flexible region that permits binding to distinct pre-let-7 loops where the GNGAY and GGAG motifs vary in their spacing. Protein interactions with both RNA sequence motifs are required for high affinity binding. [Figure: Schematic of human LIN28A and LIN28B proteins. These highly related proto-oncogenes have two distinct RNA binding regions. The first is a cold-shock domain (highlighted in blue) with preference for GNGAY RNA sequences while the CCHC Zn fingers (highlighted in green) bind preferentially to a GRAG motif (R = G or A). Binding to both RNA sites is required for high affinity pre-let-7 binding. Putative nucleolar localization signal (NoLS) and nuclear localization signal (NLS) are reported for LIN28B.] [Figure: Alignment of human pre-let-7 sequences (partial) with a focus on the terminal loop. The bases shown in red font are part of the let-7-5p/let-7-3p microRNA duplex following cytoplasmic Dicer cleavage. Black boxes and asterisks denote perfectly conserved bases while blue boxes represent bases where 10/12 are identical across all let-7 family members. Note that the GRAG (9 GGAG > 2 GAAG) motif is conserved across all family members except human let-7a-3 that is reported to escape LIN28AB-mediated repression. This RNA sequence motif is bound by the CCHC zinc fingers while the cold shock domain binds the GNGAY motif (and close variants) that lies at varying distances 5′ of the GGAG motif.] To unravel the in vivo function of Lin28ab in mammals, we in collaboration with the Daley lab generated and characterized conditional mouse knockouts of both genes (Shinoda et al., 2013). Lin28a null mice

Read the complete text